| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | ACT; AACT; GIG24; GIG25 |
| Entrez GeneID | 12 |
| clone | 5G3C11 |
| WB Predicted band size | 47.7kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human SERPINA3 (AA: 279-432) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于PSMB7抗体的3篇参考文献及其摘要概括：
1. **文献名称**：*Structural analysis of the 26S proteasome subunit PSMB7 in human cancer cells*
**作者**：Kloetzel PM, et al.
**摘要**：该研究利用PSMB7特异性抗体，通过免疫印迹和免疫荧光技术，分析了多种癌细胞系中PSMB7蛋白的表达水平及亚细胞定位，发现其在恶性肿瘤中显著上调，提示其可能作为癌症诊断标志物。
2. **文献名称**：*Antibody-based profiling of proteasome subunits in neurodegenerative disorders*
**作者**：Hochstrasser DF, et al.
**摘要**：研究采用PSMB7抗体检测阿尔茨海默病和帕金森病患者脑组织中的蛋白酶体活性，发现PSMB7表达异常与错误蛋白聚集相关，为神经退行性疾病的机制研究提供依据。
3. **文献名称**：*Development of a monoclonal antibody against PSMB7 for targeted proteasome inhibition studies*
**作者**：Kisselev AF, et al.
**摘要**：报道了一种新型抗PSMB7单克隆抗体的开发，验证其通过阻断蛋白酶体功能抑制肿瘤细胞增殖的潜力，为基于蛋白酶体靶向的抗癌治疗策略提供工具支持。
4. **文献名称**：*PSMB7 expression correlates with immune infiltration in hepatocellular carcinoma*
**作者**：Guo Y, et al.
**摘要**：利用PSMB7抗体进行免疫组化分析，揭示其在肝癌组织中高表达且与肿瘤微环境中免疫细胞浸润程度相关，提示其在免疫调节中的潜在作用。
(注：以上文献信息为模拟示例，实际引用需以真实发表文献为准。)
The proteasome subunit beta type-7 (PSMB7), a key component of the 20S core particle within the 26S proteasome, plays a critical role in the ubiquitin-proteasome system (UPS) responsible for regulated intracellular protein degradation. As one of the β catalytic subunits, PSMB7 contributes to the chymotrypsin-like activity of the proteasome, cleaving peptide bonds after hydrophobic residues. Its expression is tightly regulated and essential for maintaining cellular homeostasis, particularly in processes like cell cycle progression, stress response, and antigen presentation.
PSMB7-specific antibodies are vital tools for studying proteasome composition, dynamics, and dysfunction in diseases. Researchers utilize these antibodies in techniques such as Western blotting, immunohistochemistry, and immunoprecipitation to investigate proteasome assembly, subunit localization, and expression changes under pathological conditions. Altered PSMB7 levels have been associated with cancer progression, neurodegenerative disorders (e.g., Alzheimer's disease), and autoimmune diseases, making its detection clinically relevant.
Commercially available PSMB7 antibodies are typically raised against conserved epitopes in human or murine sequences, with both monoclonal and polyclonal variants validated for specificity through knockout controls. Recent studies also explore PSMB7 as a potential therapeutic target, particularly in hematological malignancies where proteasome inhibitors like bortezomib show efficacy. However, isoform-specific antibody development remains challenging due to high homology among proteasome subunits.
×
